Chennai Meenakshi Multispeciality Hospital Ltd vs Syngene International Ltd Stock Comparison
Chennai Meenakshi Multispeciality Hospital Ltd vs Syngene International Ltd Stock Comparison
Last Updated on: Oct 31, 2026
Key Highlights
The Latest Trading Price of Chennai Meenakshi Multispeciality Hospital Ltd is ₹ 33.15 as of 30 Oct 15:30
. The P/E Ratio of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Chennai Meenakshi Multispeciality Hospital Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Syngene International Ltd for the Sep '26 is ₹ 860.7 crore as compare to the Jun '26 revenue of ₹ 761.3 crore. This represent the growth of 13.06% The ebitda of Chennai Meenakshi Multispeciality Hospital Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Syngene International Ltd for the Sep '26 is ₹ 168.7 crore as compare to the Jun '26 ebitda of ₹ 102.6 crore. This represent the growth of 64.42% The net profit of Chennai Meenakshi Multispeciality Hospital Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0%
The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ 32.2 crore over 10 quarters. This represents a CAGR of -28.96%
The Dividend Payout of Chennai Meenakshi Multispeciality Hospital Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .
About Chennai Meenakshi Multispeciality Hospital Ltd
Chennai Meenakshi Multispeciality Hospital Limited, formerly known as Devaki Hospital Limited, was incorporated in 1990.
The Company name was changed from Devaki Hospital Limited to Chennai Meenakshi Multispeciality Hospital Limited in October, 2007.
It is a 100-bedded hospital located in the heart of Chennai at Mylapore.
The hospital has an infrastructure comprising of around 105 Beds including ICU Beds, Operating Theatre, a modern dialysis Unit besides a host of other facilities.
The Company has a pool of talented and experienced doctors who are further supported by a team of highly qualified and experienced and dedicated support staff and cutting edge technology.
The Company operate into various departments like Cardiology Department; Casualty Department; Diagnostic Services; Intensive Care Unit; Nephrology Department and Physiotherapy Department.
About Syngene International Ltd
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.
Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.
FAQs for the comparison of Chennai Meenakshi Multispeciality Hospital Ltd and Syngene International Ltd
Which company has a larger market capitalization, Chennai Meenakshi Multispeciality Hospital Ltd or Syngene International Ltd?
Market cap of Chennai Meenakshi Multispeciality Hospital Ltd is 24 Cr while Market cap of Syngene International Ltd is 16,251 Cr
What are the key factors driving the stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Syngene International Ltd?
The stock performance of Chennai Meenakshi Multispeciality Hospital Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Chennai Meenakshi Multispeciality Hospital Ltd and Syngene International Ltd?
As of October 31, 2026, the Chennai Meenakshi Multispeciality Hospital Ltd stock price is INR ₹33.15. On the other hand, Syngene International Ltd stock price is INR ₹402.6.
How do dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Syngene International Ltd compare?
To compare the dividend payouts of Chennai Meenakshi Multispeciality Hospital Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.